Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports Second Quarter 2020 Financial and Operating Results
August 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., Aug. 5, 2020 /PRNewswire/ --Â
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million Second quarter 2020 GAAP diluted EPS was $7.61 and non-GAAP diluted EPS(1) was $7.16 Initiated Phase 2 and Phase 3 clinical trials of REGN-COV2 for the treatment and prevention of COVID-19 FDA approved Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis Dupixent eosinophilic... More